bioAffinity Technologies, Inc. (BIAF) Fair Value 2026

BIAF · Services-Commercial Physical & Biological Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 10 models active

Value Trap Risk

LOW (37/100)

Quick Summary — As of 2026-07-13, bioAffinity Technologies, Inc. (BIAF) trades at $0.70, approximately 43% above CirclFi’s Bayesian DCF fair value of $0.49. QOC: 5.6/10. Value Trap Risk: 37/100 (LOW). 10/13 models active.

Key Facts

Ticker
BIAF
Price
$0.70
Quality Score
5.6/10
Value Trap Risk
37/100
Models Active
10/13
Last Updated
Strength: First Chicago suggests +288.7% upside with 21% confidence
Risk: Limited model coverage (10/13) may reduce confidence

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($0.70)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$0.49 -30.2%
CUCE Ensemble
Low Conviction
$1.31 +87.3%
First Chicago
Medium Conviction
$2.72 +288.7%
Dynamic NAV
Medium Conviction
$0.94 +35.0%

Unlock the Full Matrix

Access 6 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is bioAffinity Technologies, Inc. (BIAF) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, bioAffinity Technologies, Inc.'s intrinsic value is estimated at a composite fair value of $1.72. At a current market price of $0.70, 8 of 10 active valuation models identify upside potential, projecting an average implied return of +145.1%. Notably, Regime Cross sees the most upside at +413.8% (fair value: $3.60), while ML-RIV is the most conservative at -74.4% ($0.18). The spread between these extremes — +488.2% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About BIAF?

10 of 13 models are currently active for BIAF. Of these, 8 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates BIAF's intrinsic value at $0.49, implying -30.2% downside from the current price. See which stocks rank higher →

How Does BIAF Rank in Services-Commercial Physical & Biological Research?

Among 11 Services-Commercial Physical & Biological Research stocks, BIAF ranks #7 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

bioAffinity Technologies, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BIAF a Value Trap?

CirclFi's Value Trap algorithm assigns BIAF a score of 37/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for bioAffinity Technologies, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, bioAffinity Technologies, Inc. earns a quality score of 5.6/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +488.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BIAF valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BIAF's 10 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy bioAffinity Technologies, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Services-Commercial Physical & Biological Research Stocks Should You Also Analyze?

8 related Services-Commercial Physical & Biological Research stocks with 13-model coverage

Read investment analysis: MEDP · IQV · CRL · NRC · MXCT

Frequently Asked Questions About bioAffinity Technologies, Inc.

What is bioAffinity Technologies, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, bioAffinity Technologies, Inc. (BIAF) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.49. The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BIAF overvalued or undervalued right now?

At $0.70, 8 of 10 active models suggest BIAF may be undervalued, while 2 indicate potential overvaluation. The assessment depends on which methodology best fits bioAffinity Technologies, Inc.'s business model in Services-Commercial Physical & Biological Research.

What does a Quality of Company score of 5.6 mean for BIAF?

bioAffinity Technologies, Inc.'s QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BIAF?

CirclFi analyzes BIAF with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is BIAF a value trap in 2026?

bioAffinity Technologies, Inc.'s Value Trap score is 37/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on BIAF.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access